Area of research
Hematology · Pathology and Forensic Medicine
Research interest
Research interests include Medicine, Internal medicine, Oncology, Multiple myeloma, Lymphoma, and Daratumumab.
Incidence of severe <scp>COVID</scp> ‐19 in patients with chronic lymphocytic leukaemia or indolent B‐cell non‐Hodgkin lymphoma who received vaccination and pre‐exposure prophylaxis with tixagevimab and cilgavimab in Italy: An observational study by the <scp>GIMEMA</scp> working party on chronic lymphoproliferative disorders and by the Fondazione Italiana Linfomi
Long-Term Survival with Multiple Myeloma: An Italian Experience
Effect of daratumumab on stem cell yields in patients with newly diagnosed multiple myeloma: a report from the Multiple Myeloma Group
Severe COVID-19 Infection in Patients with Chronic Lymphocytic Leukemia or Indolent B-Cell Non-Hodgkin Lymphoma Who Received Pre-Exposure Prophylaxis with Tixagevimab and Cilgavimab in Italy: Preliminary Results of the Observational Study By the Gimema Working Party on Chronic Lymphoproliferative Disorders and By the Fondazione Italiana Linfomi
Consensus for Flow Cytometry Clinical Report on Multiple Myeloma: A Multicenter Harmonization Process Merging Laboratory Experience and Clinical Needs
P25 EFFECT OF DARATUMUMAB ON STEM CELL YIELDS IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: REPORT FROM THE MULTIPLE MYELOMA LAZIO GROUP
P505: GIMEMA AML1819 TRIAL: GEMTUZUMAB OZOGAMICIN PLUS INTENSIVE CHEMOTHERAPY IMPACTS ON THE LEVEL OF POST-CONSOLIDATION MEASURABLE RESIDUAL DISEASE (MRD) IN ACUTE MYELOID LEUKEMIA
P971: EFFECT OF DARATUMUMAB ON STEM CELL YIELDS IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: REPORT FROM THE MULTIPLE MYELOMA LAZIO GROUP.
Prevalence and Prognostic Role of IDH Mutations in Acute Myeloid Leukemia: Results of the GIMEMA AML1516 Protocol
Clinical Features and Treatment Response in Patients with Multiple Myeloma and CD20 Expression: Real-Life Experience of the Centro-Italy Multiple Myeloma Macroregional District
MiR‐22, a serum predictor of poor outcome and therapy response in diffuse large B‐cell lymphoma patients
The 47th Annual Meeting of the European Society for Blood and Marrow Transplantation: Quality Management Group – Oral Session (O175-O178)
Che-1/AATF-induced transcriptionally active chromatin promotes cell proliferation in multiple myeloma
A bronchoalveolar lavage‐driven antimicrobial treatment improves survival in hematologic malignancy patients with detected lung infiltrates: A prospective multicenter study of the SEIFEM group
Efficacy and safety of low dose ponatinib in a case of Ph‐positive acute lymphoblastic leukaemia
Prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan and stem cell transplantation: review of the evidence and suggestions
Isavuconazole: Case Report and Pharmacokinetic Considerations
The Rome Transplant Network model compared to the Italian Bone Marrow Donor Registry activity for unrelated donor search process and transplant efficiency for hematologic malignancy
Ponatinib Induces a Persistent Molecular Response and Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia with a T315I Mutation following Early Relapse after Allogeneic Transplant
Posaconazole oral suspension primary prophylaxis in acute leukemia and allogeneic stem cell transplant patients: can it be used without measurement of plasma concentration?
Prospective surveillance vs clinically driven approach for CMV reactivation after autologous stem cell transplant
Haploidentical, G-CSF Primed, Unmanipulated Bone Marrow Transplantation with Anti-CD25 Monoclonal Antibody As Part of the Gvhd Prophylaxis for Patients with High-Risk Acute Myeloid Leukemia
Evolving Criteria of Donor Selection for Allogeneic Transplant in Acute Myeloid Leukemia
Comparison between biosimilar filgrastim vs other granulocyte‐colony stimulating factor formulations (originator filgrastim, peg‐filgrastim and lenograstim) after autologous stem cell transplantation: a retrospective survey from the Rome Transplant Network
Survival of Patients with High Risk Hematological Malignancy after Allogeneic Transplant from HLA Identical Siblings Is Comparable to That of Patients Transplanted from Haploidentical, Unmanipulated Bone Marrow Donor: Results of a Matched-Pair Analysis from the Rome Transplant Network
A retrospective study on 73 elderly patients (≥75years) with aggressive B-cell non Hodgkin lymphoma: Clinical significance of treatment intensity and comprehensive geriatric assessment
Bone marrow aspiration and biopsy-related pain management
Adherence to recommendation for chemotherapy-induced nausea and vomiting prophylaxis: the proposal of a score